MAPT and Alzheimer disease: This study, of the largest number of p‐tau assays to date, provides more evidence that assays targeting p‐tau217 using several different methodologies show good agreement with one another, and consistently demonstrate greater fold‐change in AD versus non‐AD groups than those targeting other p‐tau forms.